Correlation of Blood Tumor Marker Levels with Clinical Efficacy of TACE Interventional Therapy for Primary Liver Cancer and Its Postoperative Residual Cancer Prediction Value
CHEN Tian, ZHANG Yu, LI Tingting, et al
Beijing Millennium Temple Hospital, Capital Medical University, Beijing 100038, China
Abstract：Objective: To investigate the correlation between the levels of blood tumor markers and the effect of TACE intervention for primary liver cancer (PLC) and the predictive value of the presence of residual cancer after surgery. Methods: Totally 132 primary liver cancer patients were selected as the study subjects, and they were divided into the valid group (n=40) and the ineffective group (n=92) according to the presence or absence of residual cancer after the operation, and the clinical data of the patients were collected, and the levels of serum tumor markers were detected before and after the treatment. Before and after therapy, the two groups' clinical features and blood tumor marker levels were compared; the influencing factors of the efficacy of PLC after surgery were analyzed by multifactorial logistic regression; and the predictive value of blood tumor markers for residual cancers after surgery was assessed by using the Receiver Operating Characteristic (ROC) curves. Results: The patients in the two groups had BMI, gender and the presence of cirrhotic nodules were not significant (P>0.05); the ratio of patients with differentiation degree Ⅲ~Ⅳ, as well as the levels of blood tumor markers AFP, CEA, CA125 and CA50 in the valid group were significantly higher than those in the valid group, and the tumor envelope proportion (P<0.05) was much lower than that in the successful group. Following TACE administration, there was a statistically significant difference (P<0.05) between the ineffective group's and the valid group's levels of the blood tumor markers AFP, CEA, CA125, and CA50; the results of multifactorial logistic regression analysis showed that the high levels of AFP, CA50 and CEA as well as the high degree of differentiation of the tumors were the risk factors affecting the efficacy of the treatment (P<0.05), and the tumor envelope was the protective factor for the efficacy of the treatment (P<0.05). The ROC curve showed that the area under the curve (AUC) of AFP, CEA, CA125 and CA50 for the diagnosis of residual cancer after PLC intervention were 0.917, 0.925, 0.711, and 0.617, respectively. Conclusion: The level of blood tumor markers is related to the curative effect of TACE and postoperative residual cancer, and the AUC of AFP and CEA is closer to 1, which shows that AFP and CEA have high diagnostic value for the occurrence of residual cancer after PLC intervention, and provide an important basis for the curative effect evaluation and postoperative residual cancer prediction of primary liver cancer treated by TACE
陈甜, 张裕, 李婷婷, 宋杨, 黄月. 肿瘤标志物水平与原发性肝癌TACE介入治疗效果的相关性及其对术后残癌的预测价值[J]. 河北医学, 2025, 31(12): 2037-2043.
CHEN Tian, ZHANG Yu, LI Tingting, et al. Correlation of Blood Tumor Marker Levels with Clinical Efficacy of TACE Interventional Therapy for Primary Liver Cancer and Its Postoperative Residual Cancer Prediction Value. HeBei Med, 2025, 31(12): 2037-2043.
[1] Kong Y,Zhu X,Zhang X,et al.Traditional Chinese medicine combined with radiofrequency ablation improves primary liver cancer outcomes:a systematic review with meta-analysis[J].Heliyon,2023,9(8):e18591. [2] Wang N,Liu Q,Che F,et al.Establishment and methodological evaluation of a chemiluminescence assay for detection of anti-envelope protein (E1,E2) antibodies in the serum of hepatitis C virus-infected patients[J].Journal of Clinical Laboratory Analysis,2024,38(4):25011. [3] 董亚宁,朱菊芳,毛珂,等.基于深度学习的3D超分辨率重建技术的MRI影像组学预测TACE联合分子靶向药物治疗不可切除肝癌的疗效[J].磁共振成像,2024,15(12):124-130. [4] Hao J,Sang J,Xu X,et al.Diagnostic value of CT and MRI combined with serum LDH,NSE,CEA,and MYCN in pediatric neuroblastoma[J].World Journal of Surgical Oncology,2023,21(0):251. [5] Feng J,Jiang J.Deep learning-based chest CT image features in diagnosis of lung cancer[J].Computational and Mathematical Methods in Medicine,2022,2022(10):4153211. [6] Liu T,Meng G,Ma S,et al.Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma[J].Frontiers in Immunology,2024,15(10):1455716. [7] 周鑫,张涵,徐静.动态监测循环肿瘤细胞在肝癌患者术后随访中的作用[J].医学研究与战创伤救治,2025,38(3):273-277. [8] Pericleous S,Bhogal R H,Mavroeidis V K.The role of circulating biomarkers in the early detection of recurrent colorectal cancer following resection of liver metastases[J].Frontiers in Bioscience (Landmark Edition),2022,27(6):189. [9] Bindeman W E,Fingeton B.Glycosylation as a regulator of site-specific metastasis[J].Cancer Metastasis Reviews,2022,41(1):107-129. [10] 李臻,李一帆,余鹏,等.经动脉载药微球化疗栓塞治疗大肝癌疗效的影响因素[J].介入放射学杂志,2023,32(8):781-785.
2025, Vol. 31 
冀公网安备13080202000786号